Analysts expect Aileron Therapeutics Inc (NASDAQ:ALRN) to announce ($0.24) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aileron Therapeutics’ earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.26). Aileron Therapeutics posted earnings of ($0.50) per share in the same quarter last year, which suggests a positive year over year growth rate of 52%. The firm is expected to issue its next earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Aileron Therapeutics will report full-year earnings of ($1.14) per share for the current year, with EPS estimates ranging from ($1.27) to ($1.03). For the next financial year, analysts expect that the company will report earnings of ($0.87) per share, with EPS estimates ranging from ($0.91) to ($0.81). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Aileron Therapeutics.
Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.03).
In other news, SVP Kathryn Gregory bought 45,000 shares of the stock in a transaction on Tuesday, August 13th. The shares were bought at an average price of $0.65 per share, with a total value of $29,250.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Rickenbach Josef H. Von bought 113,145 shares of the stock in a transaction on Friday, September 13th. The stock was purchased at an average cost of $0.98 per share, for a total transaction of $110,882.10. Insiders have purchased 265,211 shares of company stock worth $207,650 over the last ninety days. 6.20% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in ALRN. Deutsche Bank AG grew its position in shares of Aileron Therapeutics by 432.9% during the fourth quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock worth $108,000 after purchasing an additional 104,932 shares in the last quarter. Jennison Associates LLC grew its position in shares of Aileron Therapeutics by 649.6% during the first quarter. Jennison Associates LLC now owns 2,040,255 shares of the company’s stock worth $3,828,000 after purchasing an additional 1,768,073 shares in the last quarter. BlackRock Inc. grew its position in shares of Aileron Therapeutics by 179.6% during the second quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock worth $36,000 after purchasing an additional 31,787 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Aileron Therapeutics by 261.6% during the second quarter. Vanguard Group Inc. now owns 333,005 shares of the company’s stock worth $240,000 after purchasing an additional 240,910 shares in the last quarter. Hedge funds and other institutional investors own 26.00% of the company’s stock.
NASDAQ:ALRN traded down $0.13 during mid-day trading on Tuesday, reaching $0.80. The stock had a trading volume of 101,519 shares, compared to its average volume of 389,224. The firm has a 50 day moving average price of $0.74 and a two-hundred day moving average price of $1.11. The stock has a market capitalization of $24.86 million, a P/E ratio of -0.39 and a beta of 2.27. Aileron Therapeutics has a one year low of $0.44 and a one year high of $3.23. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.04 and a current ratio of 6.04.
About Aileron Therapeutics
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Further Reading: Monthly Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.